A real‑world pharmacovigilance study of raloxifene based on the FDA adverse event reporting system (FAERS)

Raloxifene was approved for the treatment of postmenopausal osteoporosis; however, its safety profile remains inadequately understood. This study aimed to evaluate the safety signals associated with raloxifene.